<DOC>
	<DOC>NCT02303093</DOC>
	<brief_summary>Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%</brief_summary>
	<brief_title>Non-Interventional Octagam® 10% - GAM10-06 "GammaTrack"</brief_title>
	<detailed_description>A Non-Interventional Study on the Tolerability and Efficacy of octagam® 10%. Patients with any indication (replacement and immonomodulation) as described by the treating physician. Marketed Octagam 5% or 10% will be used according to the investigator prescription; intravenous (iv) administration.The primary objective is to detect and evaluate adverse drug reactions (ADRs) occurring during or after the administration of Octagam in any indication, age group or treatment regimen, where a causal relationship to the administration of Octagam is suspected.</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Immunoglobulins, Intravenous</mesh_term>
	<mesh_term>Rho(D) Immune Globulin</mesh_term>
	<criteria>Any patient who needs to be treated with a product of this class because of his/her medical condition and whom the treating physician decides to prescribe Octagam regularly, may be included.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>